Typhoid VI polysaccharide vaccine
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Typhoid VI polysaccharide vaccine
- bacillus typhi
- Bacillus typhi
- salmonella choleraesuis typhi
- Salmonella choleraesuis typhi
- salmonella enterica ser typhi
- Salmonella enterica ser. typhi
- salmonella enterica serovar typhi
- Salmonella enterica serovar typhi
- salmonella typhi
- Salmonella typhi
- Salmonella Typhi
- salmonella typhi vectored pneumonia vaccine
- Salmonella Typhi-vectored pneumonia vaccine
- salmonella typhimurium
- Salmonella typhimurium
- Salmonella Typhimurium
- salmonella typhosa
- Salmonella typhosa
- Ty800 (Salmonella typhi) Oral Vaccine
- ty800 salmonella typhi oral vaccine
- typhoid vaccine
- Typhoid vaccine
- Typhoid Vaccine
- typhoid vaccine antigens
- Typhoid vaccine antigens
And 4 more, listed on the interactive page.
- ChEMBL ID
- CHEMBL2108822
- RxNorm IDs (RxCUI)
- 807219
- First in class
- No
- Orphan designation
- No
- Condition
- Malaria
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Hepatitis A
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007305
- Subject identifier
- D006506
- Condition identifier
- EFO_0000195
- Condition identifier
- EFO_0000319
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001068
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001358
- Condition identifier
- EFO_0007305
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009429
- Condition identifier
- EFO_0009429
- Highest recorded phase
- 4
- Condition identifier
- EFO_0600064
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001418
- Highest recorded phase
- 4
- Condition identifier
- HP_0100806
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002050
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006502
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0043905
- Highest recorded phase
- 1
- Event
- abortion
- Reports
- 3
- Reporting signal score
- 16.632
- Event
- urticaria chronic
- Reports
- 3
- Reporting signal score
- 21.8683
- NCT00197249
- NCT03917654
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (47)
- A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants
- Challenge Non-Typhoidal Salmonella (CHANTS) Study
- Cognitive, Emotional, and Neural Responses to Acute Inflammation
- Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood
- Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines
- CVD 909 Vi Prime Boost Study
- Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation
- Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women
- Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women
- Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
- IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
- Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
- Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)
- Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso
- Inflammation and Threat Sensitivity in PTSD
- Inflammatory Challenge and Fear
- Influence of Dietary Nitrate on Vascular Dysfunction and Inflammation
In development for (8)
- Acute respiratory distress syndrome Phase 1
- Cancer Phase 1
- Cardiovascular disorder Phase 1
- Depressive disorder Phase 1
- Hepatitis A virus infection Phase 3
- Major depressive disorder Phase 1
- Malaria Phase 2
- Pneumonitis Phase 1
Other linked conditions (1)
- Post-traumatic stress disorder